Compare AMBA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBA | ELVN |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2011 | 2020 |
| Metric | AMBA | ELVN |
|---|---|---|
| Price | $58.34 | $48.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $97.25 | $43.40 |
| AVG Volume (30 Days) | 615.5K | ★ 1.7M |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.32 | 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $295,402,000.00 | N/A |
| Revenue This Year | $15.03 | N/A |
| Revenue Next Year | $12.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.81 | $14.79 |
| 52 Week High | $96.69 | $46.31 |
| Indicator | AMBA | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 74.97 |
| Support Level | $50.86 | $17.99 |
| Resistance Level | $71.00 | N/A |
| Average True Range (ATR) | 2.05 | 2.66 |
| MACD | 1.14 | 0.40 |
| Stochastic Oscillator | 90.09 | 97.64 |
Ambarella Inc is a developer of low-power system-on-a-chip, or SoC, semiconductors and software for edge and physical artificial intelligence (AI) applications and intelligent automation. Its products are used in a wide variety of human viewing, computer vision for edge and physical AI applications, including a variety of video security cameras, automotive camera systems, fixed robots, autonomous mobile robots (AMRs), industrial applications, intelligent transportation systems, and consumer devices, such as action, drone and 360 degree cameras. The company operates as a single operating and reportable segment and derives substantially all of its revenue from development and sales of low-power AI-based processing and video and image processing SoC solutions.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.